Oncolys BioPharma Inc.
4588.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$174.82B
Close$
$126.32
97.9% downside
Current Fair Value
97.9% downsideOvervalued by 97.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $174.82 Billion |
|---|---|
| Enterprise Value | $172.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-80 |
| Beta | 1.19 |
| Outstanding Shares | 29,292,315 |
Return
| Return on Equity | -46.26% |
|---|---|
| Return on Assets | -33.41% |
| Return on Invested Capital | -44.72% |
Valuation & Multiples
| P/E Ratio | -108.62 |
|---|---|
| PEG | 354.01 |
| Price to Sales | 351.18 |
| Price to Book Ratio | 53.78 |
| Enterprise Value to Revenue | 343.45 |
| Enterprise Value to EBIT | -114.66 |
| Enterprise Value to Net Income | -115 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Oncolys BioPharma Inc.
42 employees
CEO: Yasuo Urata Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions,...